MEDICLINIC INTERNATIONAL PLC Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
('Mediclinic', the 'Company'or the 'Group')
18 June 2018
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Awards granted under the Company's Short-Term Incentive Scheme
and Long-Term Incentive Plan
On 15 June 2018, awards over ordinary shares in Mediclinic (the 'Shares') were granted to the following Directors and other persons discharging managerial responsibilities ('PDMRs') under the Company's Short-Term Incentive Scheme (the 'STI') and Long-Term Incentive Plan (the 'LTIP'), approved by shareholders in July 2017:
Name | Director/ PDMR | Number of Shares awarded under the STI | Number of Shares awarded under the LTIP |
Dr Ronnie van der Merwe | Director | n/a | 200,128 |
Jurgens Myburgh | Director | 27,236 | 110,646 |
Danie Meintjes | Director | 45,811 | 209,998 |
David Hadley | PDMR | n/a | 26,422 |
Gert Hattingh | PDMR | n/a | 43,956 |
Magnus Oetiker | PDMR | n/a | 59,701 |
Koert Pretorius | PDMR | n/a | 48,121 |
Dr Dirk le Roux | PDMR | n/a | 34,586 |
Dr Ole Wiesinger | PDMR | n/a | 32,409 |
The awards made under the STI and LTIP were granted for nil consideration and are based on the average of the middle-market quotations of a Share during a period of five dealing days ending with the dealing day before the day of grant, which equates to £5.58 per Share.
The vesting of awards under the STI is subject to employment conditions only; no further performance conditions apply. Awards granted under the LTIP are structured as conditional awards, with vesting being subject to the satisfaction of performance conditions over a three-year period. Executive Directors of Mediclinic will be required to hold vested awards for a further two years (i.e. until the fifth anniversary of grant).
The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.
1. | Details of PDMR / person closely associated with them ('PCA') | |||||
a) | Name | Dr Carel Aron van der Merwe | ||||
2. | Reason for the notification | |||||
a) | Position / status | Chief Executive Officer of the Company | ||||
b) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mediclinic International plc | ||||
b) | LEI | 2138002S5BSBIZTD5I60 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 200,128 £nil | ||||
e) | Date of the transaction | 15 June 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1. | Details of PDMR / person closely associated with them ('PCA') | |||||
a) | Name | Petrus Jurgens Myburgh | ||||
2. | Reason for the notification | |||||
a) | Position / status | Chief Financial Officer of the Company | ||||
b) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mediclinic International plc | ||||
b) | LEI | 2138002S5BSBIZTD5I60 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Short Term Incentive Scheme | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 27,236 £nil | ||||
e) | Date of the transaction | 15 June 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 110,646 £nil | ||||
e) | Date of the transaction | 15 June 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1. | Details of PDMR / person closely associated with them ('PCA') | |||||
a) | Name | Daniël Petrus Meintjes | ||||
2. | Reason for the notification | |||||
a) | Position / status | Executive Director of the Company | ||||
b) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mediclinic International plc | ||||
b) | LEI | 2138002S5BSBIZTD5I60 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Short Term Incentive Scheme | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 45,811 £nil | ||||
e) | Date of the transaction | 15 June 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 209,998 £nil | ||||
e) | Date of the transaction | 15 June 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1. | Details of PDMR / person closely associated with them ('PCA') | |||||
a) | Name | David John Hadley | ||||
2. | Reason for the notification | |||||
a) | Position / status | Chief Executive Officer - Mediclinic Middle East | ||||
b) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mediclinic International plc | ||||
b) | LEI | 2138002S5BSBIZTD5I60 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 26,422 £nil | ||||
e) | Date of the transaction | 15 June 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1. | Details of PDMR / person closely associated with them ('PCA') | |||||
a) | Name | Gert Cornelis Hattingh | ||||
2. | Reason for the notification | |||||
a) | Position / status | Chief Corporate Services Officer of the Mediclinic Group | ||||
b) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mediclinic International plc | ||||
b) | LEI | 2138002S5BSBIZTD5I60 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 43,956 £nil | ||||
e) | Date of the transaction | 15 June 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1. | Details of PDMR / person closely associated with them ('PCA') | |||||
a) | Name | Magnus Ulrich Oetiker | ||||
2. | Reason for the notification | |||||
a) | Position / status | Chief Human Resources Officer of the Mediclinic Group | ||||
b) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mediclinic International plc | ||||
b) | LEI | 2138002S5BSBIZTD5I60 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 59,701 £nil | ||||
e) | Date of the transaction | 15 June 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1. | Details of PDMR / person closely associated with them ('PCA') | |||||
a) | Name | Koert Hendrik Stefanus Pretorius | ||||
2. | Reason for the notification | |||||
a) | Position / status | Chief Executive Officer - Mediclinic Southern Africa | ||||
b) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mediclinic International plc | ||||
b) | LEI | 2138002S5BSBIZTD5I60 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 48,121 £nil | ||||
e) | Date of the transaction | 15 June 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1. | Details of PDMR / person closely associated with them ('PCA') | |||||
a) | Name | Dr Dirk Cornelius le Roux | ||||
2. | Reason for the notification | |||||
a) | Position / status | Chief Information Officer of the Mediclinic Group | ||||
b) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mediclinic International plc | ||||
b) | LEI | 2138002S5BSBIZTD5I60 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 34,586 £nil | ||||
e) | Date of the transaction | 15 June 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1. | Details of PDMR / person closely associated with them ('PCA') | |||||
a) | Name | Dr Thorsten Ole Wiesinger | ||||
2. | Reason for the notification | |||||
a) | Position / status | Chief Executive Officer - Hirslanden | ||||
b) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mediclinic International plc | ||||
b) | LEI | 2138002S5BSBIZTD5I60 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 32,409 £nil | ||||
e) | Date of the transaction | 15 June 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.
Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers:Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Attachments
- Original document
- Permalink
Disclaimer
Mediclinic International plc published this content on 18 June 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 18 June 2018 10:07:02 UTC
